drugset / Trial / NCT06268652
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
RandomizedParallel-groupOpen-labelPrevention
Summary
This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer.
Timeline
- Start
- 2024-01-15
- Primary completion
- 2026-02-15
- Completion
- 2028-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Comparator | Vinorelbine | Small molecule | 60 mg/m2 | Intravenous |